结直肠癌术后循环肿瘤细胞检测的临床意义

doi:10.3760/cma.j.issn.2095-7041.2019.06.013

摘要
图/表
参考文献
相关文章 (4)

全文: PDF (1788 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨结直肠癌(CRC)患者术后外周血循环肿瘤细胞(CTCs)阳性率及其计数与临床病理特征、肿瘤复发转移及预后之间的关系及其临床意义。方法回顾性分析2016年1月—2017年7月上海交通大学医学院附属第九人民医院首诊并经病理确诊的99例CRC患者的临床资料,其中男66例、女33例,年龄37~79岁。检测患者术后4~8周且辅助治疗前CTCs计数和血清癌胚抗原(CEA)水平,随访患者生存情况,比较患者不同临床病理学特征患者间CTCs表达及计数值的统计学差异,包括性别、年龄、原发灶部位、肿瘤分化程度、原发灶浸润深度(T分期)、区域淋巴结侵袭程度(N分期)、远处转移(M分期)、TNM总分期;观察患者生存情况;采用COX比例风险回归模型进行无进展生存期、总生存期的单因素和多因素分析。结果 99例CRC患者CTCs阳性率为60.6%(60/99),CTCs计数值为0~24(4.909±5.518)。患者的CTCs阳性率和CTCs计数值在T1+T2+T3期、N0期、M0期、Ⅰ~Ⅱ期、CEA＜5 ng/mL和中高分化组患者低于T4期、N1+N2期、M1期、Ⅲ~Ⅳ期、CEA≥5 ng/mL、低分化组患者,差异均有统计学意义(P值均＜0.05)。患者随访3~20个月,死亡22例(22/99,22.2%),其中CTCs阳性21例;疾病进展32例(32/99,32.3%),其中CTCs阳性29例。单因素分析显示:CTCs表达、N分期、M分期、肿瘤分期、和高CEA水平是无进展生存期的影响因素(P值均＜0.05);CTCs表达、N分期、M分期、肿瘤原发灶位于直肠、高CEA水平是总生存期的影响因素(P值均＜0.05)。CTCs和远处转移是CRC患者无进展生存期和总生存期的独立预后因素(HR= 5.418、2.254,95%可信区间:1.595~8.403、1.227~7.986,P值均＜0.05)。结论在术后CRC患者中,CTCs表达与预后不良有关,对肿瘤复发转移评估具有一定的价值和临床意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王丽丽
	刘峰
	张燕捷
	袁海花
	姜斌

关键词 ：结直肠肿瘤, 循环肿瘤细胞, 生存分析, 预后因素

Abstract：Objective To evaluate the relationship between peripheral blood circulation tumor cells (CTCs) and clinical pathological variables, tumor recurrence and metastasis and prognosis in patients with colorectal cancer (CRC).Methods From January 2016 to July 2017, the clinical pathological variables of 99 newly-diagnosed and histopathologically confirmed CRC patients from the Ninth People's Hospital affiliated to Shanghai jiao tong university medical school were collected. There were 66 males and 33 females, aged 37-79 years old. The CTCs enumeration and the serum carcinoembryonic antigen (CEA) levels were measured between 4 and 8 weeks after surgery or before adjuvant therapy. All patients were followed up for survival. Statistical differences in characteristics and CTCs enumeration, including gender, age, primary site, tumor differentiation, primary invasive depth (T stage), regional lymph node invasion (N stage), distant metastasis (M Staging), TNM staging, observation of patient survival, COX proportional hazards regression model for single-factor and multivariate analysis of progression-free survival and overall survival.Results The positive rate of CTCs in 99 CRC patients was 60.6% (60/99), and the range of CTCs was 0-24 (4.909±5.518). CTCs in patients with positive expression and CTCs count stage T1+T2, T3, N0, M0, Ⅰ-Ⅱ period, the CEA＜5 ng/mL were lower than those of T4, N1+N2, M1 period, Ⅲ-Ⅳ period, the CEA acuity 5 ng/mL, low differentiation, and the differences were statistically significant (all P values＜0.05). The patients were followed up for 3 to 20 months, and 22 patients died (22/99, 22.2%),including 21 CTCs positive; 32 patients with disease progression (32/99,32.3%), of which 29 were positive for CTCs. Univariate analysis showed that CTCs, N stage, M stage, tumor stage, and high serum CEA levels were the influencing factors of poor progression-free survival (all P values＜0.05). CTCs, N stage, M stage, primary tumor stage and high CEA levels were the influencing factors of poor overall survival (all P values＜0.05). CTCs and distant metastasis were independent prognostic factors for poor progression-free survival and overall survival in CRC patients (HR=5.418,2.254,95% confidence interval: 1.595-8.403,1.227-7.986, all P values＜0.05).Conclusions In patients with postoperative CRC,CTCs enumeration might be a predictive factor for tumor recurrence and metastasis. CTCs positive might be associated with a reduced survival in patients with colorectal cancer.

Key words： Colorectal neoplasms Circulating tumor cells Survival Predictive factor

收稿日期: 2019-04-06

基金资助:上海市申康中心“促进市级医院临床技能与临床创新三年行动计划”项目(16CR4030A);上海交通大学医学院附属第九人民医院种子基金(JYZZ008)

通讯作者: 姜斌,Email: jiangbinwcr@163.com

引用本文:

王丽丽, 刘峰, 张燕捷, 袁海花, 姜斌. 结直肠癌术后循环肿瘤细胞检测的临床意义[J]. 中华解剖与临床杂志, 2019, 24(6): 588-595.
Wang Lili, Liu Feng, Zhang Yanjie, Yuan Haihua, Jiang Bing. Clinical significance of detection of circulating tumor cells after colorectal cancer surgery. Chinese Journal of Anatomy and Clinics, 2019, 24(6): 588-595.

链接本文:

http://www.cjac.com.cn/CN/10.3760/cma.j.issn.2095-7041.2019.06.013 或 http://www.cjac.com.cn/CN/Y2019/V24/I6/588

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. DOI:10.3322/caac.21442.
[2]	Tzeng CW, Aloia TA. Colorectal liver metastases[J]. J Gastrointest Surg, 2013, 17(1): 195-201; quiz p.201-202. DOI:10.1007/s11605-012-2022-3.
[3]	Nagasaka T, Mishima H, Sawaki A, et al. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study[J]. BMJ Open, 2016, 6(6): e011454. DOI:10.1136/bmjopen-2016-011454.
[4]	Nakayama G, Ishigure K, Yokoyama H, et al. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)[J]. BMC Cancer, 2017, 17(1): 243. DOI:10.1186/s12885-017-3245-1.
[5]	Takata K, Fujita KI, Kubota Y, et al. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan[J]. J Pharm Health Care Sci, 2016, 2: 30. DOI:10.1186/s40780-016-0064-5.
[6]	Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(10): 1065-1075. DOI:10.1016/S1470-2045(14)70330-4.
[7]	Hazama S, Nakamura Y, Tanaka H, et al. A phase Ⅱstudy of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)[J]. J Transl Med, 2014,12: 108. DOI:10.1186/1479-5876-12-108.
[8]	Jeong KY, Kim EK, Park MH, et al. Perspective on cancer therapeutics utilizing analysis of circulating tumor cells[J]. Diagnostics (Basel), 2018, 8(2). DOI:10.3390/diagnostics8020023.
[9]	Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of circulating tumor cells in cancer[J]. Mol Oncol, 2016, 10(3): 408-417. DOI:10.1016/j.molonc.2016.01.010.
[10]	Liu H, Zhang X, Li J, et al. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells[J]. J Cancer Res Clin Oncol, 2015, 141(2): 189-201. DOI:10.1007/s00432-014-1752-x.
[11]	Weng D, Penzner JH, Song B, et al. Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers[J]. Breast Cancer Res, 2012, 14(1): R18. DOI:10.1186/bcr3102.
[12]	Hinz S, Hendricks A, Wittig A, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients-a prospective study[J]. BMC Cancer, 2017, 17(1): 53. DOI:10.1186/s12885-016-3035-1.
[13]	Di Meo A, Bartlett J, Cheng Y, et al. Liquid biopsy: a step forward towards precision medicine in urologic malignancies[J]. Mol Cancer, 2017, 16(1): 80. DOI:10.1186/s12943-017-0644-5.
[14]	Pesta M, Kulda V, Narsanska A, et al. May CTC technologies promote better cancer management?[J]. EPMA J, 2015, 6(1): 1. DOI:10.1186/s13167-014-0023-x.
[15]	Gorges TM, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients[J]. Cancer Immunol Immunother, 2013, 62(5): 931-939. DOI:10.1007/s00262-012-1387-1.
[16]	Yap TA, Lorente D, Omlin A, et al. Circulating tumor cells: a multifunctional biomarker[J]. Clin Cancer Res, 2014, 20(10): 2553-2568. DOI:10.1158/1078-0432.CCR-13-2664.
[17]	Borowski DW, Banky B, Banerjee AK, et al. Intra-arterial methylene blue injection into ex vivo colorectal cancer specimens improves lymph node staging accuracy: a randomized controlled trial[J]. Colorectal Dis, 2014, 16(9): 681-689. DOI:10.1111/codi.12681.
[18]	Brahimi-Horn MC, Bellot G, Pouysségur J. Hypoxia and energetic tumour metabolism[J]. Curr Opin Genet Dev, 2011, 21(1): 67-72. DOI:10.1016/j.gde.2010.10.006.
[19]	Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization[J]. Microvasc Res, 2010, 79(3): 217-223. DOI:10.1016/j.mvr.2010.01.007.
[20]	Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization[J]. Microvasc Res, 2010, 79(3): 217-223. DOI:10.1016/j.mvr.2010.01.007.
[21]	Das A, Kunkel M, Joudeh J, et al. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation[J]. Cancer Biol Ther, 2015, 16(5): 709-713. DOI:10.1080/15384047.2015.1030555.
[22]	Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(19): 3213-3221. DOI:10.1200/JCO.2007.15.8923.
[23]	Huang X, Gao P, Song Y, et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis[J]. BMC Cancer, 2014, 14: 976. DOI:10.1186/1471-2407-14-976.
[24]	Galizia G, Gemei M, Orditura M, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients[J]. J Gastrointest Surg, 2013, 17(10): 1809-1818. DOI:10.1007/s11605-013-2258-6.
[25]	Lu CY, Uen YH, Tsai HL, et al. Molecular detection of persistent postoperative circulating tumour cells in stages Ⅱ and Ⅲ colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse[J]. Br J Cancer, 2011, 104(7): 1178-1184. DOI:10.1038/bjc.2011.40.
[26]	Yalcin S, Kilickap S, Portakal O, et al. Determination of circulating tumor cells for detection of colorectal cancer progression or recurrence[J]. Hepatogastroenterology, 2010, 57(104): 1395-1398.
[27]	Uen YH, Lu CY, Tsai HL, et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage Ⅰ-Ⅲ colorectal cancer after curative resection[J]. Ann Surg Oncol, 2008, 15(8): 2120-2128. DOI:10.1245/s10434-008-9961-7.
[28]	Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24 Suppl 6: vi64-vi72. DOI:10.1093/annonc/mdt354.
[29]	You KY, Huang R, Ding PR, et al. Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0[J]. Int J Colorectal Dis, 2014, 29(4): 529-538. DOI:10.1007/s00384-014-1831-0.
[30]	Magni E, Botteri E, Ravenda PS, et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery[J]. Int J Colorectal Dis, 2014, 29(9): 1053-1059. DOI:10.1007/s00384-014-1958-z.
[31]	Wallwiener M, Riethdorf S, Hartkopf AD, et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients[J]. BMC Cancer, 2014,14:512. DOI:10.1186/1471-2407-14-512.
[32]	Lack J, Gillard M, Cam M, et al. Circulating tumor cells capture disease evolution in advanced prostate cancer[J]. J Transl Med, 2017, 15(1): 44. DOI:10.1186/s12967-017-1138-3.
[33]	Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry[J]. Cytometry A, 2011, 79(2): 107-117. DOI:10.1002/cyto.a.21014.
[34]	Hardingham JE, Grover P, Winter M, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer—20 years of progress[J]. Mol Med, 2015, 21 Suppl 1(Suppl 1): S25-S31. DOI:10.2119/molmed.2015.00149.